Neuritek is developing therapies for a wide range of psychiatric disorders, initially focusing on PTSD.
Neuritek’s therapeutic model: innovative, efficient, and
solution-oriented.
State of the art facilities. Clinical and research labs.
Established academic and industry collaborations. We bring academic and industry knowledge to our patients.
Rich drug pipeline. Immediate drug candidates based upon their proven relevance to PTSD
10 years of proprietary PTSD research. A new approach to drug development process.
Although several psychotherapies are available to treat PTSD, novel pharmacotherapy development has lagged and only recently have intensive basic science and clinical studies yielded novel, potentially breakthrough discoveries that have the potential to introduce a new era for trauma survivors with PTSD.
Neuritek’s clinical development program is based on a substantial body of scientific data that have directly implicated the body’s own cannabinoid system in the development of PTSD.
We focus our research and development efforts on activating the body’s own cannabinoid system–a complex network of receptors, molecules, and enzymes that work together to help maintain cellular balance, or homeostasis, within our bodies. This balance allows cells, organs, and systems to function optimally.
PTSD is characterized by reduced function of the body's own cannabinoid system as a result of trauma and stress, leading to the symptoms of PTSD. Neuritek’s approach to treating PTSD is to activate the body’s own cannabinoid system and bring back to normal its reduced function.
We anticipate that results of the proposed treatment development will have potential relevance and applicability in treating other psychiatric syndromes beside PTSD that are linked to high stress.